Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma
- 8 November 2013
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (4) , 579-586
Abstract
Risk‐adapted, response‐based therapies for pediatric Hodgkin lymphoma have resulted in 5‐year survival exceeding 90%. Although high‐dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk‐stratified, response‐based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579–586.Keywords
This publication has 44 references indexed in Scilit:
- Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin LymphomaJAMA, 2012
- Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignanciesPediatric Blood & Cancer, 2011
- BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology GroupBlood, 2011
- Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962Transplantation and Cellular Therapy, 2011
- Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphomaAnnals of Oncology, 2010
- Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patientsCancer, 2010
- Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institutionLeukemia & Lymphoma, 2010
- Current Approaches to the Management of Pediatric Hodgkin LymphomaPediatric Drugs, 2010
- A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Blood, 2009
- Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group ReportJournal of Clinical Oncology, 2009